Journals / Journal of Neurological Sciences (Turkish) / 2012 / Cilt: 29 - Sayı: 1

Tüm Beyin Radyoterapisi Sonrasi Progrese Beyin Metastazlarinda İkinci Seri Radyoterapi: Steriotaktik Radyo-Cerrahi Sonuçları

Re-Irradiation of Progressive Brain Metastases After Whole Brain Radiotherapy: Outcome of Stereotactic Radiosurgery

Pages
82–91
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Median 1800 (800- 2400) cGy dosage of SRS was used in 44 cases (68%) inone fraction, and in 21 cases (32%) in two fractions.Result: For 12 patients, progression occurred within the SRS field, and overall local controlwas 80%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: In our study, rates of and factors affecting survival obtained by frameless roboticstereotactic radiosurgery are investigated retrospectively in progressive brain metastasespreviously treated with total cranial radiotherapy.Materials and Methods: SRS was given as salvage therapy to 60 patients with brainmetastases after WBRT.
📊
Key Findings & Data:Median 1800 (800- 2400) cGy dosage of SRS was used in 44 cases (68%) inone fraction, and in 21 cases (32%) in two fractions.Result: For 12 patients, progression occurred within the SRS field, and overall local controlwas 80%.
💡
Conclusion & Impact:In the multivariance analysis, younger age andsmaller tumor size were significantly related with better survival.Conclusion: In the progressive brain metastases, patients with relatively limited lifeexpectancy, SRS is a preferable alternative with 12 months median survival.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: In our study, rates of and factors affecting survival obtained by frameless roboticstereotactic radiosurgery are investigated retrospectively in progressive brain metastasespreviously treated with total cranial radiotherapy.Materials and Methods: SRS was given as salvage therapy to 60 patients with brainmetastases after WBRT. CyberKnife® radiosurgical system (Accuray, Sunnyvale, CA) wasused for SRS. Median 1800 (800- 2400) cGy dosage of SRS was used in 44 cases (68%) inone fraction, and in 21 cases (32%) in two fractions.Result: For 12 patients, progression occurred within the SRS field, and overall local controlwas 80%. Survival rate was 85% at sixth months, and 52% in 12th months (median 12.5months). Significantly better survival rates were achieved in the patients who breastcarcinoma was the primary tumor site. Survival rates significantly decreased if the systemicdisease showed progression. A significant change in survival was not observed in differentRecursive Partitioning Analysis (RPA) groups, however for Score Index for Radiosurgery(SIR) survival, there was a significant relation. In the multivariance analysis, younger age andsmaller tumor size were significantly related with better survival.Conclusion: In the progressive brain metastases, patients with relatively limited lifeexpectancy, SRS is a preferable alternative with 12 months median survival.

Özet

Amaç: Çalışmamızda daha önce total kranial radyoterapi ile tedavi edilmiş progresif beyinmetastazlarında "frameless" robotik steriotaktik radiyo-cerrahi(SRS) ile sonuçları vesağkalıma etki eden faktörlerin retrospektif olarak değerlendirilmesi amaçlanmıştır.Materyal Metod: Steriotaktik radyocerrahi 60 hastada tüm beyin radyoterapisi(TBRT)sonrası salvaj tedavi olarak, CyberKnife® radiosurgical system (Accuray, Sunnyvale, CA)ileuygulanmıştır. Kırkdört (%68)hastada 1 fraksiyon, 21 (%32)hastada 2 fraksiyon ile 1800(800-2400) cGy kullanılmıştır.Sonuçlar: Hastaların 12 sinda progresyon SRS sahasında ouşmuş olup local kontron %80elde edilmiştir. Sağkalım 6 ayda %85, 12 ayda %52 ,median 12.5 ay saptanmıştır. Memekarsinomu metastazlarında anlamlı daha iyi sağkalım saptanmış olup, sistemik hastalıkkontrolde değil ise sağkalım anlamlı olarak kötüleşmiştir. Recursive Partitioning Analysis(RPA) gruplarının sağkalıma etkisi gösterilemez iken Score Index for Radiosurgery (SIR)sağkalımla anlamlı ilşkili bulunmuştur. Çok değişkenli analizde genç yaş ve küçük tumorboyutu iyi sağkalımla ilişkili bulunmuştur.Tartışma: Sınırlı sağkalım beklentisi olan progresif beyin metastazlarında SRS 12 aylıksağkalım ile tercih edilebilir bir alternatiftir.

🔖

Cite This Article

MAYADAĞLI, A., GEMİCİ, C., KOÇAK, M., GÜL, Ş., IŞIK, N. Ö., GEDİK, D. (2022). Tüm Beyin Radyoterapisi Sonrasi Progrese Beyin Metastazlarinda İkinci Seri Radyoterapi: Steriotaktik Radyo-Cerrahi Sonuçları. Journal of Neurological Sciences (Turkish), Cilt: 29 - Sayı: 1, 82–91. https://ajindex.com/articles/565435

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Akyurek S, Chang EL, Mahaj an A, Hassenbusch SJ, Allen PK, Mathews LA et al: Stereotactic radiosurgical treatment of cerebral metastases arising f rom breast cancer. Am J Clin Oncol, 2007, 30(3):310–314
  2. Ammirati M, Cobbs CS, Linskey ME, Paleologos NA, et al: The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical p ractice guideline J Neurooncol,2010,96: 85–96
  3. Andrews D W, Scott CB, Sp erduto P W, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boosts f or p atients with one to three brain metastases: Phase III results of the RTOG 9508 randomized trial. Lancet, 2004, 363: 1665–72
  4. Barker FG: Surgical and radiosurgical management of brain metastases. Surg Clin North Am., 2005, 85: 329–345
  5. Bindal RK, Sawaya R, Leavens ME, Hess KR, Taylor SH: Reop eration f or recurrent metastatic brain tumors. J Neurosurg, 1995, 83(4):600–604
  6. Chao ST, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Neyman G, Reuther AM, Suh JH: Salvage stereotactic radiosurgery eff ectively treats recurrences f rom whole-brain radiation therapy. Cancer., 2008, 113(8): 2198–204
  7. Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J: Treatment of cerebral metastases f rom breast cancer with stereotactic radiosurgery. Strahlenther Onkol, 2004, 180(9):590–596
  8. Coop er JS, Steinf eld AD, Lerch IA: Cerebral metastases: value of reirradiation in selected p atients. Radiology, 1990, 174(3: Pt 1):883–885
  9. Davey P, Schwartz ML, Scora D, Gardner S, O'Brien PF: Fractionated (sp lit dose) radiosurgery in p atients with recurrent brain metastases: Imp lications f or survival. Br J Neurosurg, 2007, 21(5):491–495
  10. Delattre JY, Krol G, Thaler HT, Posner JB: Distribution of brain metastases. Arch Neurol, 1988, 45(7):741–4
  11. Deutsch M, Parsons JA, Mercado R: Radiotherapy f or intracranial metastases. Cancer, 1974, 34(5): 1607–11
  12. Gasp ar LE, Scott C, Rotman M, et al: Recursive p artitioning analysis (RPA) of prognostic f actors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys, 1997, 37: 745–51
  13. Gasp ar LE, Scott C, Murray K, Curran W: Validation of the RTOG recursive p artitioning analysis (RPA) classif ication f or brain metastases. Int J Radiat Oncol Biol Phys, 2000, 47(4): 1001–6
  14. Gasp ar LE, Mehta MP, Patchell RA, et al: The roEge Üniversitesi Nöroşirüle of whole brain radiation the